Bachem Holding (BANB) 주식 개요
Bachem Holding AG는 자회사와 함께 전 세계 제약 및 생명공학 회사에 연구, 임상 개발 및 상업적 응용을 위한 제품을 제공합니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 BANB에 대한 위험이 감지되지 않았습니다.
BANB Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
CHF 249.99
FV
73.2% 저평가 내재 할인율62.01%
Revenue growth p.a.
150
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Bachem Holding AG 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | CHF 67.10 |
| 52주 최고가 | CHF 83.25 |
| 52주 최저가 | CHF 48.52 |
| 베타 | 0.79 |
| 1개월 변동 | -12.17% |
| 3개월 변동 | 8.05% |
| 1년 변동 | 16.19% |
| 3년 변동 | -17.62% |
| 5년 변동 | -35.23% |
| IPO 이후 변동 | 379.29% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 05
BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework
Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.
내러티브 업데이트 • May 22
BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside
Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.
내러티브 업데이트 • May 01
BANB: Future Earnings Execution Is Expected To Support CHF 80 Upside Potential
Analysts have nudged their price target on Bachem Holding slightly higher, with recent Street research indicating a CHF 5 increase from both Barclays and Deutsche Bank to CHF 80, supported by updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a CHF 80 target as aligned with their updated view on fair value, suggesting that current assumptions on growth and margins justify a higher valuation anchor.Recent updates
내러티브 업데이트 • Jun 05
BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework
Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.내러티브 업데이트 • May 22
BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside
Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.내러티브 업데이트 • May 01
BANB: Future Earnings Execution Is Expected To Support CHF 80 Upside Potential
Analysts have nudged their price target on Bachem Holding slightly higher, with recent Street research indicating a CHF 5 increase from both Barclays and Deutsche Bank to CHF 80, supported by updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a CHF 80 target as aligned with their updated view on fair value, suggesting that current assumptions on growth and margins justify a higher valuation anchor.
새로운 내러티브 • Apr 26
Bachem Holding - The Purest Public Peptide Play?
We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.내러티브 업데이트 • Apr 16
BANB: Future Upside Will Depend On Executing Profit Margin Assumptions
Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.내러티브 업데이트 • Apr 02
BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential
Narrative Update Analyst price targets for Bachem Holding have shifted to a range of CHF 60 to CHF 80, with the upper end raised from CHF 75, as analysts reflect updated views on the company in their valuation work. Analyst Commentary Recent research updates on Bachem Holding point to a split in how analysts see the risk and reward around the stock, which feeds directly into the current CHF 60 to CHF 80 price target range.내러티브 업데이트 • Mar 19
BANB: Future Execution On Growth Plans Will Support Higher CHF 80 Upside Potential
Analysts have nudged the consolidated price target for Bachem Holding to CHF 80, up CHF 5 from prior levels, citing updated assumptions for growth, profitability and a slightly lower P/E outlook that align with recent Street research moves. Analyst Commentary Street research on Bachem Holding has been mixed, with some analysts lifting price targets toward CHF 80 while others are more hesitant and keep targets closer to CHF 60.내러티브 업데이트 • Mar 05
BANB: Future Execution On Pipeline Plans Will Support Higher Market Confidence
The updated analyst price target for Bachem Holding suggests a modest upward revision to fair value to CHF 78.66, with analysts citing slightly adjusted assumptions for the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a signal that their assumptions for Bachem Holding’s future earnings and cash flows now support a fair value above the prior level, even after revisiting discount rate and P/E inputs.내러티브 업데이트 • Feb 18
BANB: Future Pipeline Execution Will Drive Upside Versus Recent Cautious Views
Analysts have adjusted their fair value estimate for Bachem Holding to CHF 76.59, reflecting updated views on growth, profitability and valuation following recent price target revisions that include a CHF 32 increase from RBC Capital and a reduction to CHF 60 from Barclays. Analyst Commentary Recent research shows a split view on Bachem Holding, with some bullish analysts lifting targets and more cautious voices trimming expectations.내러티브 업데이트 • Feb 04
BANB: Higher Fair Value Will Rely On Execution Of Existing Order Book
Analysts have raised their fair value estimate for Bachem Holding from CHF 100.00 to CHF 110.00, citing updated assumptions around revenue growth, profit margins and future P/E multiples that are in line with recent Street target changes, including the higher price target from RBC and the revised level from Barclays. Analyst Commentary Recent research updates around Bachem Holding give you a mixed but useful read on how the Street is thinking about valuation and execution.내러티브 업데이트 • Jan 21
BANB: Building K Execution Risks Will Limit Future Share Upside
Analysts have nudged their price target on Bachem Holding slightly lower to about CHF 60 to CHF 75, reflecting updated assumptions around discount rates, revenue growth near 21.5% and an expected future P/E close to 18.9%. They are also weighing recent research that includes a reduced CHF 60 target alongside a CHF 75 target tied to the company’s Building K expansion plans.내러티브 업데이트 • Jan 07
BANB: Building K Execution Risk Will Constrain Future Upside Potential
Analysts have trimmed their average price target on Bachem Holding to CHF 60 from CHF 75, citing updated assumptions for revenue growth, profit margins and future P/E multiples that reflect a more measured outlook, even as expansion projects remain in focus. Analyst Commentary Recent street research on Bachem highlights a mix of views, with some analysts seeing potential tied to expansion projects such as Building K, while others are recalibrating expectations and price targets to reflect what they view as a more balanced risk and reward profile.내러티브 업데이트 • Dec 14
BANB Building K Expansion Will Define Future Upside And Execution Risk
Analysts have raised their price target for Bachem Holding from approximately CHF 58 to about CHF 75, citing increased confidence in revenue growth driven by the company's Building K expansion project, despite a slightly higher discount rate and modestly lower profit margin and valuation multiples. Analyst Commentary Recent research commentary highlights a more constructive stance on Bachem Holding, with the upgraded price target to CHF 75 framed around the growth potential from the Building K expansion project.분석 기사 • Dec 01
At CHF51.85, Is Bachem Holding AG (VTX:BANB) Worth Looking At Closely?
While Bachem Holding AG ( VTX:BANB ) might not have the largest market cap around , it received a lot of attention from...분석 기사 • Oct 25
Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings
Bachem Holding AG's ( VTX:BANB ) price-to-earnings (or "P/E") ratio of 32x might make it look like a strong sell right...내러티브 업데이트 • Sep 26
Building K Production Will Serve Peptide And Oligonucleotide Therapies
Bachem Holding's fair value has been revised downward, primarily reflecting slight declines in both its discount rate and future P/E ratio, with the consensus analyst price target decreasing from CHF77.88 to CHF74.70. What's in the News Maintained 2026 sales guidance of over CHF 1 billion and profitability above 30%.분석 기사 • Sep 18
Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Aug 16
Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly
SWX:BANB 1 Year Share Price vs Fair Value Explore Bachem Holding's Fair Values from the Community and select yours Some...분석 기사 • Jul 30
Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues
The market for Bachem Holding AG's ( VTX:BANB ) stock was strong after it released a healthy earnings report last week...분석 기사 • Jul 25
Bachem Holding AG's (VTX:BANB) P/E Is Still On The Mark Following 28% Share Price Bounce
Bachem Holding AG ( VTX:BANB ) shares have continued their recent momentum with a 28% gain in the last month alone. But...
새로운 내러티브 • Mar 02
Building K And 24-Hour Operations Will Improve Efficiency
Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides.주주 수익률
| BANB | CH Life Sciences | CH 시장 | |
|---|---|---|---|
| 7D | 0.1% | -1.7% | 2.5% |
| 1Y | 16.2% | -10.1% | 12.6% |
수익률 대 산업: BANB은 지난 1년 동안 -10.1%의 수익을 기록한 Swiss Life Sciences 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: BANB은 지난 1년 동안 12.6%를 기록한 Swiss 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| BANB volatility | |
|---|---|
| BANB Average Weekly Movement | 5.7% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 2.4% |
안정적인 주가: BANB는 지난 3개월 동안 Swiss 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: BANB의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1971 | 2,363 | Anne-Kathrin Stoller | www.bachem.com |
바켐 홀딩은 자회사와 함께 전 세계 제약 및 생명공학 회사에 연구, 임상 개발 및 상업적 응용을 위한 제품을 제공합니다. 펩타이드 및 올리고뉴클레오티드 신화학물질(NCE)과 같은 펩타이드 활성 의약품 성분의 개발, 생산 및 규제 지원에 관여하고 있습니다. 또한 상업용 NCE 및 제네릭, 프로젝트 관리, 품질 및 규제, 분석, 우수 의약품 제조 관리 기준 생산, 연구용 생산, 공급 및 수직 통합 서비스도 제공합니다.
Bachem Holding AG 기초 지표 요약
| BANB 기초 통계 | |
|---|---|
| 시가총액 | CHF 5.03b |
| 순이익 (TTM) | CHF 148.79m |
| 매출 (TTM) | CHF 695.07m |
33.8x
주가수익비율(P/E)7.2x
주가매출비율(P/S)BANB는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| BANB 손익계산서 (TTM) | |
|---|---|
| 매출 | CHF 695.07m |
| 매출원가 | CHF 495.34m |
| 총이익 | CHF 199.73m |
| 기타 비용 | CHF 50.94m |
| 순이익 | CHF 148.79m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
Jul 30, 2026
| 주당순이익(EPS) | 1.99 |
| 총이익률 | 28.74% |
| 순이익률 | 21.41% |
| 부채/자본 비율 | 3.9% |
BANB의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
1.3%
현재 배당 수익률45%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/17 14:40 |
| 종가 | 2026/06/17 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Bachem Holding AG는 17명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Charles Pitman | Barclays |
| Estelle Bétrisey | Berenberg |
| Patrick Laager | Berenberg |